Boston, MA 09/24/2014 (wallstreetpr) – Pharmaceutical company, Avanir Pharmaceuticals Inc (NASDAQ:AVNR) said that it would be raising a little over $200 million from the issue of fresh shares to the general public. It would use the funds for general corporate purposes. The issue announcement comes on the heels of the company announcing favorable Phase II study results of its AVP-923 for treating the agitation in patients.
Public Offering
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) said that it would issue 18.2 million shares to the public, which was fully underwritten, its statement revealed. The company has priced the share at $11.00 before any discounts of underwriting.
Avanir Pharmaceuticals also indicated that it has given an option of 30-days to the underwriters to acquire an additional 2.73 million shares in connection with the public issue. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) indicated that it was selling shares and that there was no other stakeholder involved in selling of shares.
The issue, which would be anticipated to close on or before September 29, would generate gross proceeds of $200.2 million. This excluded the options provided to the underwriters, and in case the underwriters chose to acquire them, Avanir Pharmaceuticals Inc (NASDAQ:AVNR) would get an additional $30 million from the issue.
Issue Managers
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) indicated that apart from using the funds for its general corporate purposes, it would also use the funds for commercial activities of NUEDEXTA, future clinical studies, and the commercial launch of AVP-825 on approval from the regulator. It would use the funds to partly payoff its debt besides investing or acquiring in complementary products or businesses.
The joint book-running managers to the issue were Deutsche Bank Securities, J.P. Morgan and Bank of America Merrill Lynch while JMP Securities and Piper Jaffray acted as co-managers to the issue.
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) said that shelf registration statement in connection with the issue of shares was filed with the regulator and became effective automatically on September 22. It said that the prospectus were filed with the Securities and Exchange Commission and can be accessed through its website.
